Machine Learning-based Dose Prediction in [Lu]Lu-PSMA-617 Therapy by Integrating Biomarkers and Radiomic Features from [Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography.
Journal:
International journal of radiation oncology, biology, physics
Published Date:
May 18, 2025
Abstract
PURPOSE: The study aimed to develop machine learning (ML) models for pretherapy prediction of absorbed doses (ADs) in kidneys and tumoral lesions for patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing [Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy (RLT). By leveraging radiomic features (RFs) from [Ga]Ga-PSMA-11 (Ga-PSMA) positron emission tomography/computed tomography (PET/CT) scans and clinical biomarkers (CBs), the approach has the potential to improve patient selection and tailor dosimetry-guided therapy.
Authors
Keywords
No keywords available for this article.